At a major international menopause congress, researchers presented findings that quietly deflate a widely held hope: that testosterone, the body's own anabolic signal, might serve as a pharmaceutical remedy for the muscle loss that quietly diminishes so many women's later years. The PAMELA trial — rigorous, well-powered, and carefully designed — found that physiologic-dose testosterone offered little meaningful improvement in muscle strength or function in healthy postmenopausal women, a result that neither closes the question nor confirms the promise. It is a reminder that biological plausibi
Testosterone Shows Limited Benefit for Postmenopausal Women's Muscle Mass
Testosterone did not improve lower-limb muscle power.
Mark
So the study was large and well-designed, but the results were basically negative. Why does that matter?
Mimi
Because for years, testosterone has been promoted as a solution for muscle loss in midlife women, but most of the evidence was weak—small studies, inconsistent dosing, unclear methods. This trial finally tested it properly, and it didn't work the way people hoped.
Luke
But it's important to note: this was a study of healthy, active women who were already in good shape. We don't know if testosterone would help someone who's sedentary or deconditioned.
Mark
So the results might not apply to the women who actually need help most?
Mimi
Exactly. The women in the study were already doing relatively well. They had good muscle reserve. If you're trying to recruit for a rigorous trial, you need people who meet strict criteria, and that often means healthier people.
Luke
And there's another gap: the study didn't combine testosterone with resistance training. We know resistance training is the most effective intervention, but we don't know if testosterone could amplify that effect.
Mark
So this study answers one question—does testosterone alone work?—but leaves another question open.
Mimi
Right. And the researchers are thinking about that next trial. But it would be much harder to run, because you can't blind people to whether they're doing resistance training.
Luke
The other thing worth noting: the one area where testosterone did show a difference was hip and thigh lean mass, but it was only 60 grams. That's about two ounces. We don't know if that's clinically meaningful.
Mark
So even where it worked, the effect was tiny.
Mimi
Yes. And for the primary outcome—lower-limb muscle power, which is what actually matters for function and preventing falls—there was no effect at all.
The Pulse
- Sarcopenia quietly strips postmenopausal women of strength, independence, and metabolic resilience — and fewer than one in ten meet even the minimum exercise threshold that could slow it.
- Testosterone's anabolic reputation made it a compelling candidate for a pharmaceutical shortcut, but the PAMELA trial's primary outcome — lower-limb muscle power — showed no improvement over placebo.
- Two modest signals emerged from the noise: dynamic balance improved and hip-thigh lean mass increased by 60 grams, but researchers themselves flagged the clinical meaning of these gains as unknown.
- The trial's well-selected, already-healthy participants may have left the most vulnerable women — sedentary, deconditioned, muscle-depleted — outside the frame of what was actually tested.
- The most promising path forward may be a harder one: a future trial pairing testosterone with resistance training to see whether the hormone amplifies what exercise alone begins.
At a major international menopause congress, researchers presented findings that quietly deflate a widely held hope: that testosterone, the body's own anabolic signal, might serve as a pharmaceutical remedy for the muscle loss that quietly diminishes so many women's later years. The PAMELA trial — rigorous, well-powered, and carefully designed — found that physiologic-dose testosterone offered little meaningful improvement in muscle strength or function in healthy postmenopausal women, a result that neither closes the question nor confirms the promise. It is a reminder that biological plausibility and clinical proof are separated by a distance that only careful science can cross.
At the International Menopause Society Congress in Brazil, Dr. Hayley Dillon presented findings from the PAMELA trial — one of the largest and most rigorous studies yet conducted on testosterone's capacity to build muscle in postmenopausal women. The 26-week, double-blind, placebo-controlled study enrolled 146 women aged 55 to 70, dosed to bring testosterone levels into the premenopausal range, and tracked multiple measures of muscle strength, mass, and function. The answer it returned was largely discouraging.
The urgency behind the question is real. Women begin losing muscle in their 30s, arrive at older age with less reserve than men, and after menopause often see the decline accelerate — not necessarily from hormonal change itself, but from the behavioral shifts that symptoms provoke. By their 80s, women develop sarcopenia at higher rates than men, with consequences that include falls, fractures, disability, and metabolic dysfunction. Resistance training remains the most effective intervention, yet only one in ten postmenopausal women meets the minimum recommended dose. Testosterone, anabolic by nature and declining with age, seemed like a plausible bridge.
The trial tested that plausibility carefully. Adherence was high, testosterone levels reached their target, and researchers measured not just one outcome but five domains of muscle function. Yet the primary measure — lower-limb muscle power assessed by vertical jump mechanography — showed no difference between the testosterone and placebo groups. Three of five secondary outcomes were similarly unchanged. Only dynamic balance and lean soft tissue in the hips and thighs showed any advantage, the latter by a mere 60 grams — a difference the researchers themselves described as of unknown clinical significance.
Two questions from the audience pointed toward what the trial could not resolve: whether less healthy, more sedentary women might respond differently, and whether testosterone might prove additive when paired with a resistance training stimulus. Neither can be answered here. The study population was already relatively fit, limiting how broadly the findings can be applied. Researchers are weighing a future trial combining testosterone with exercise, though blinding such a study presents its own challenges.
The conclusion is careful but clear: physiologic-dose testosterone offers limited benefit as a standalone strategy for muscle preservation in healthy, active postmenopausal women. The data are preliminary — not yet peer-reviewed — but they represent exactly the kind of rigorous inquiry women have long deserved. Whether those who have promoted testosterone as a broader remedy will engage honestly with these results is, as yet, an open question.
At the International Menopause Society Congress in Brazil, researchers presented findings from one of the largest and most rigorous studies yet conducted on testosterone's ability to build muscle in postmenopausal women. The PAMELA trial, a 26-week randomized, double-blind, placebo-controlled study, tested whether a female-specific testosterone product dosed to match premenopausal levels could strengthen and enlarge muscle in women aged 55 to 70. The answer, presented by Dr. Hayley Dillon, was largely no.
The question driving the research is urgent. Women lose muscle steadily beginning in their 30s, but they arrive at older age with less muscle to begin with than men do. After menopause, the decline accelerates—not necessarily because of menopause itself, but because symptoms and behavioral changes often reduce the activities that preserve muscle. Women also tend to fall short of protein intake targets. By their 80s, women develop sarcopenia—the clinical term for age-related muscle loss and weakness—at higher rates than men. Sarcopenia carries real consequences: falls, fractures, disability, loss of independence, and metabolic dysfunction. The most effective prevention is resistance training, yet only one in five postmenopausal women do it regularly, and only one in ten meet the minimum recommended dose. Testosterone seemed like a plausible pharmaceutical bridge. It is anabolic, meaning it directly builds muscle through androgen receptor signaling. It also converts to estradiol, which might help indirectly. And testosterone itself declines with age, just as muscle does.
But plausibility is not proof. The PAMELA trial was designed to test whether this logic held up in real women. Researchers screened 414 women and ultimately randomized 152, with 146 completing the full 26 weeks. The study population was relatively narrow: naturally postmenopausal women, mostly of European descent, already healthy and active, willing to maintain their usual diet and exercise habits. The primary outcome was lower-limb muscle power, measured by two-leg vertical jump mechanography. Secondary outcomes included grip strength, muscle mass, neuromuscular quickness, dynamic balance, and static balance.
The testosterone group achieved the intended dosing—levels rose to the premenopausal range—and adherence was high. Yet the primary outcome showed no effect. Testosterone did not improve lower-limb muscle power compared to placebo. Of five secondary measures, three showed no difference: grip strength, neuromuscular quickness, and static balance. Two measures favored testosterone: dynamic balance improved, and lean soft tissue in the hips and thighs increased by 60 grams. The researchers themselves noted that the magnitude of these differences is small and of unknown clinical significance. In five other body sites measured and in whole-body lean mass, testosterone had no impact.
The study's strengths are substantial. It was two to five times larger than prior trials. The investigators confirmed that testosterone levels reached the target range and that women adhered to the protocol. They measured multiple domains of muscle function, not just one outcome. Yet the limitations matter too. The women enrolled were already relatively fit and healthy, with good muscle reserve. They were not sedentary or deconditioned. They were not representative of all postmenopausal women.
Two questions from the audience pointed to gaps the trial could not answer. One researcher asked whether less active, less healthy women might benefit more from testosterone—whether the hormone might help those with less muscle to begin with. Another wondered whether testosterone might work better when combined with resistance training, providing an additive effect if there were a training stimulus to amplify. Neither question can be answered by this trial. The researchers are considering a future study pairing testosterone with resistance training, though such a trial would be harder to execute and recruit for, since resistance training cannot be blinded.
The conclusion is measured but clear: physiologic-dose testosterone provides limited support as a strategy to improve muscle mass and function in relatively healthy, active postmenopausal women. This is preliminary data—the study has not yet been published in a peer-reviewed journal—but it is the kind of rigorous, well-designed research that women have rightly demanded. Whether those promoting testosterone as a cure-all will accept the results, apply different standards to this study than to lower-quality research favoring their preferred outcome, or simply ignore it, remains an open question.
Notable Quotes
The authors concluded the study provides limited support for physiologic-dose testosterone as a strategy to improve muscle mass and function for relatively healthy, active postmenopausal women.— PAMELA trial researchers
Researchers are considering creating a trial involving testosterone in addition to resistance training.— Dr. Hayley Dillon
Want the full story?
Read the original at The Vajenda ↗